# Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma

> **NCT02345408** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 54 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** CCX872-B

## Key facts

- **NCT ID:** NCT02345408
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2020-05-06
- **Final completion:** 2020-05-06
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02345408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02345408, "Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02345408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*